Alnylam Pharmaceuticals (ALNY) Convertible Debt (2022 - 2026)

Alnylam Pharmaceuticals' Convertible Debt history runs 5 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• Quarterly Convertible Debt fell 1.58% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 1.58% YoY) and the FY2025 annual result came in at $1.0 billion, down 1.64% from the prior year.
• Convertible Debt was $1.0 billion for Q1 2026 at Alnylam Pharmaceuticals, roughly flat from $1.0 billion in the prior quarter.
• Across five years, Convertible Debt topped out at $1.0 billion in Q3 2025 and bottomed at $1.0 billion in Q4 2025.
• A 5-year average of $1.0 billion and a median of $1.0 billion in 2023 frame the typical range for Convertible Debt.
• Peak annual rise in Convertible Debt reached 1.62% in 2025, while the deepest fall reached 1.64% in 2025.
• Alnylam Pharmaceuticals' Convertible Debt stood at $1.0 billion in 2022, then gained by 0.38% to $1.0 billion in 2023, then advanced by 0.38% to $1.0 billion in 2024, then slipped by 1.64% to $1.0 billion in 2025, then advanced by 0.16% to $1.0 billion in 2026.
• Business Quant data shows ALNY's Convertible Debt at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $1.0 billion in Q3 2025.